News Releases

December 1, 2014

RepliCel Life Sciences Receives Health Canada Clearance for Clinical Trial in Patients with Chronic Achilles Tendinosis
Health Canada Issues “No Objection Letter” for RepliCel’s Phase 1/2 Clinical Trial of RCT-01 VANCOUVER, BC – December 1, 2014 – RepliCel Life Sciences... Read full article

November 26, 2014

RepliCel Announces 2014 Third Quarter Financial Results
VANCOUVER, BC – November 26, 2014 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (TSXV:RP) (OTCQB: REPCF), a clinical stage regenerative medicine company... Read full article

October 29, 2014

RepliCel Submits Clinical Trial Application to Health Canada for its Chronic Achilles Tendinosis Trial
Autologous cell therapy, RCT-01, to be investigated for treatment of tendinopathies refractory to other treatments VANCOUVER, BC – October 29, 2014 – RepliCel Life... Read full article

October 9, 2014

RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum
Japanese meetings to focus on partnering VANCOUVER, BC – October 9, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage... Read full article

October 7, 2014

RepliCel Life Sciences Adds Industry Specialist to Management Team
Newly Appointed Vice-President of Business & Corporate Development to Drive External Initiatives VANCOUVER, BC – October 7, 2014 – RepliCel Life Sciences Inc. (OTCQB:... Read full article

October 2, 2014

RepliCel to Present Clinical Trial Update at Stem Cell Meeting on the Mesa Partnering Forum in California
VANCOUVER, BC – October 2, 2014 – RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), clinical stage regenerative medicine company focused on the development... Read full article

September 12, 2014

RepliCel Retains Market-Making Services
VANCOUVER, BC – September 12, 2014 – RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF) (“RepliCel” or the “Company”) has, subject to regulatory approval,... Read full article

September 9, 2014

RepliCel Garners Feature on Fox Business News and the Financial Post
RepliCel’s Innovative Technology Converts Your Own Cells into Products to Repair and Rejuvenate the Body VANCOUVER, BC – September 9, 2014 – RepliCel Life... Read full article

September 4, 2014

RepliCel to Present at Rodman & Renshaw’s 16th Annual Global Investment Conference in New York
VANCOUVER, BC – September 4, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the development... Read full article

September 3, 2014

RepliCel Life Sciences Joins Centre for Commercialization of Regenerative Medicine, Industry Consortium
CCRM and RepliCel to Partner on Development of Cell Therapies for Tendon Repair VANCOUVER, BC and Toronto, ON – September 3, 2014 – RepliCel... Read full article